Article

Victoza® LEAD Clinical Trial Program

Victoza® studies included nearly 4000 patients in the Liraglutide Effect and Action in Diabetes (LEAD) trials. Click here for more information.

Related Videos
Related Content
Sleepless, man suffering from insomnia, sleep apnea or stress. Tired and exhausted guy. Headache or migraine. Awake in the night.
December 20th 2024

FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity

Luke Halpern, Assistant Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Varicella zoster or chickenpox virus, ai illustration. A herpes virus which cause chickenpox and shingles - Image credit: Cristina | stock.adobe.com
December 20th 2024

Study: Fatal Disseminated Herpes Zoster in Immunocompetent Individuals

Kennedy Ferruggia, Assistant Editor
Public Health Matters podcast logo
September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor
Women With History of Gestational Diabetes Found to Have Less Inflammatory Diets
December 20th 2024

Women With History of Gestational Diabetes Found to Have Less Inflammatory Diets

Aislinn Antrim, Assistant Managing Editor